- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Locked nucleic acid.
Displaying page 1 of 1.
EudraCT Number: 2010-019057-17 | Sponsor Protocol Number: SPC3649-203 | Start Date*: 2010-07-13 |
Sponsor Name:Santaris Pharma A/S | ||
Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered ... | ||
Medical condition: Patients infected with chronic hepatitis C | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) DE (Completed) SK (Completed) PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004741-17 | Sponsor Protocol Number: SPC2996-101 | Start Date*: 2005-05-09 |
Sponsor Name:Santaris Pharma | ||
Full Title: SPC2996 in Chronic Lymphocytic Leukaemia An open-labelled, international multicenter dose escalating, phase I/II study of SPC2996, an LNA antisense molecule against Bcl-2, in patients with relapsed... | ||
Medical condition: Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in adults in the US and most of Western Europe. The incidence is 8100 to 12500 new cases in the US per year. CLL is a relatively ind... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004686-28 | Sponsor Protocol Number: 14143JK-AS | Start Date*: 2018-07-16 |
Sponsor Name:Belfast Health and Social Care Trust (BHSCT) | ||
Full Title: A randomised, double-blind, placebo-controlled trial to evaluate the effect of Epstein-Barr virus suppression in chronic obstructive pulmonary disease (EViSCO trial). | ||
Medical condition: Epstein-Barr virus infection in patients with chronic obstructive pulmonary disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-001353-17 | Sponsor Protocol Number: SPC2996-107 | Start Date*: 2008-11-05 | ||||||||||||||||
Sponsor Name:Santaris Pharma A/S | ||||||||||||||||||
Full Title: A PHASE I/II, OPEN LABEL STUDY OF SPC2996 IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED FOLLICULAR OR LYMPHOPLASMACYTIC NON-HODGKIN’S LYMPHOMA | ||||||||||||||||||
Medical condition: Follicular Lymphoma (FL); Lymphoplasmacytic (lymphoplasmacytoid) Lymphoma (LPL) / Waldenstrom’s macroglobulinemia (WM) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) HU (Prematurely Ended) CZ (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
